全球智库信息集成服务系统(G2TT): Impact of DNA patents on pharmacogenomics research and development: economic and policy issues.

G2TT

来源类型	Article
规范类型	其他
DOI	10.1002/ddr.20419
ISBN	02724391
	Impact of DNA patents on pharmacogenomics research and development: economic and policy issues.
	Paci, Daniele; Hopkins, Michael M; Zika, Eleni; Ibarreta, Dolores
发表日期	2010-12
出处	Drug Development Research
出版年	2010
页码	485-491
语种	英语
摘要	The science of pharmacogenetics and pharmacogenomics (or collectively PGx) has advanced rapidly in recent years, and some technologies based on these developments have entered into use. It is notable that these advances have occurred in parallel with related advances in genetic testing, led by developments in testing services for the diagnosis of rare disorders that share Mendelian patterns of inheritance. However, a profusion of patents on nucleotide sequences (often termed ¿gene patents¿) has led to widespread concern that disputes over intellectual property could hamper the development and diffusion of these technologies. This article outlines the recent evidence from major empirical studies on the complex landscape of diagnostic DNA patents in the United States and Europe and discusses the traditional arguments in favor and against gene patenting in PGx and genetic testing. It also explores the extent to which concerns in clinical genetics might be relevant to PGx. We find that although recent evidence on genetic testing suggests that many of the issues might have been overestimated or overemphasized, no dedicated studies have been published on the intellectual property aspects of PGx. Drug Dev Res 71: 485¿491, 2010. © 2010 Wiley-Liss, Inc.
URL	http://sro.sussex.ac.uk/id/eprint/17847/
来源智库	Science Policy Research Unit (United Kingdom)
引用统计
资源类型	智库出版物
条目标识符	http://119.78.100.153/handle/2XGU8XDN/467781
推荐引用方式 GB/T 7714	Paci, Daniele,Hopkins, Michael M,Zika, Eleni,et al. Impact of DNA patents on pharmacogenomics research and development: economic and policy issues.. 2010.